Algorae Pharmaceuticals Ltd (asx:1AI) Share Price

Company Profile

Business description
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Contact
525 Collins Street
Level 23, Rialto South Tower
MelbourneVIC3000
AUS
T: +61 422180317
https://www.algoraepharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
48

Recommended

From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.

Malik Ahmed Khan, CFA | 24 April 2026

Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.

Mark Taylor | 24 April 2026

ChatGPT and large language models should be a tailwind for this company.

Simonelle Mody | 24 April 2026

Index	Last price	Change	% Change
All Ordinaries	8,986.10	15.90	0.18%
CAC 40	8,157.82	69.50	-0.84%
DAX 40	24,128.98	26.47	-0.11%
Dow JONES (US)	49,230.71	79.61	-0.16%
FTSE 100	10,379.08	77.93	-0.75%
HKSE	25,911.02	67.05	-0.26%
NASDAQ	24,836.60	398.10	1.63%
Nikkei 225	60,443.15	726.97	1.22%
NZX 50 Index	12,874.94	9.99	-0.08%
S&P 500	7,165.08	56.68	0.80%
S&P/ASX 200	8,761.30	12.10	0.14%
SSE Composite Index	4,084.59	4.69	0.12%